{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:46:04Z","timestamp":1760244364425,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["UID\/Multi\/04349\/2020","PTDC\/QUI-NUC\/30147\/2017","PTDC\/QUI-OUT\/32243\/2017","PTDC\/QUI-OUT\/3854\/2021"],"award-info":[{"award-number":["UID\/Multi\/04349\/2020","PTDC\/QUI-NUC\/30147\/2017","PTDC\/QUI-OUT\/32243\/2017","PTDC\/QUI-OUT\/3854\/2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Virus-like particles (VLPs) are nanoplatforms comprised of one or more viral proteins with the capacity to self-assemble without viral genetic material. VLPs arise as promising nanoparticles (NPs) that can be exploited as vaccines, as drug delivery vehicles or as carriers of imaging agents. Engineered antibody constructs, namely single-chain variable fragments (scFv), have been explored as relevant molecules to direct NPs to their target. A vector containing the scFv of an antibody, aimed at the human epidermal growth factor receptor 2 (HER2) and fused to the human immunodeficiency virus (HIV) protein gp41, was previously constructed. The work herein describes the early results concerning the production and the characterization of HIV-1-based VLPs expressing this protein, which could function as potential non-toxic tools for transporting drugs and\/or imaging agents.<\/jats:p>","DOI":"10.3390\/bioengineering9110713","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:33:32Z","timestamp":1669005212000},"page":"713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of HER2-Specific HIV-1-Based VLPs"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0575-2650","authenticated-orcid":false,"given":"Sofia A.","family":"Martins","sequence":"first","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"}]},{"given":"Joana","family":"Santos","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-5289","authenticated-orcid":false,"given":"Sandra","family":"Cabo Verde","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"},{"name":"Departamento de Engenharia e Ci\u00eancias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4906","authenticated-orcid":false,"given":"Jo\u00e3o D. G.","family":"Correia","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"},{"name":"Departamento de Engenharia e Ci\u00eancias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-1007","authenticated-orcid":false,"given":"Rita","family":"Melo","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, ao km 139,7, 2695-066 Loures, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Le, D.T., and Muller, K.M. (2021). In Vitro Assembly of Virus-Like Particles and Their Applications. Life, 11.","DOI":"10.3390\/life11040334"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-Like Particles: Preparation, Immunogenicity and Their Roles as Nanovaccines and Drug Nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-virology-100114-055141","article-title":"Virus-Based Nanoparticles as Versatile Nanomachines","volume":"2","author":"Koudelka","year":"2015","journal-title":"Annu. Rev. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/protein\/gzq069","article-title":"Virus Engineering: Functionalization and Stabilization","volume":"24","author":"Mateu","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1021\/acs.bioconjchem.0c00240","article-title":"The Protein Corona Does Not Influence Receptor-Mediated Targeting of Virus-like Particles","volume":"31","author":"Hejtmankova","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/btm2.10049","article-title":"Virus-Like Particles: Next-Generation Nanoparticles for Targeted Therapeutic Delivery","volume":"2","author":"Rohovie","year":"2017","journal-title":"Bioeng. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro1464","article-title":"Multidrug-Resistance Efflux Pumps\u2014Not Just for Resistance","volume":"4","author":"Piddock","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAI.0b013e31820b844e","article-title":"CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells","volume":"56","author":"Franco","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e0134321","DOI":"10.1128\/JVI.01343-21","article-title":"Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses","volume":"96","author":"Bontjer","year":"2022","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21637","DOI":"10.1073\/pnas.2008156117","article-title":"Rapid Formation of Human Immunodeficiency Virus-Like Particles","volume":"117","author":"Bednarska","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3389\/fcimb.2022.997875","article-title":"How Promising Are HIV-1-Based Virus-Like Particles for Medical Applications?","volume":"12","author":"Martins","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Santos, J., Cardoso, M., Moreira, I.S., Goncalves, J., Correia, J.D.G., Verde, S.C., and Melo, R. (2021). Integrated In Silico and Experimental Approach Towards the Design of A Novel Recombinant Protein Containing an Anti-HER2 scFv. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073547"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1007\/s00253-019-10038-3","article-title":"Production of HIV-1-Based Virus-Like Particles for Vaccination: Achievements and Limits","volume":"103","author":"Cervera","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_15","unstructured":"Scientific, T. (2022, November 10). Improve Lentiviral Production Using Lipofectamine 3000 Reagent. Available online: https:\/\/www.thermofisher.com\/pt\/en\/home\/life-science\/cell-culture\/cell-culture-learning-center\/cell-culture-resource-library\/cell-culture-transfection-application-notes\/improve-lentiviral-production-using-lipofectamine-3000-reagent.html."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, W.Y., Yin, S., Huang, S.W., Yang, M.H., Chen, P.M., Wu, S.R., Welsher, K., Yang, H., and Arthur Chen, Y.M. (J. Microbiol. Immunol. Infect., 2022). The Trajectory Patterns of Single HIV-1 Virus-Like Particle in Live CD4 Cells: A Real Time Three-Dimensional Multi-Resolution Microscopy Study Using Encapsulated Nonblinking Giant Quantum Dot, J. Microbiol. Immunol. Infect., online ahead of print.","DOI":"10.1016\/j.jmii.2022.08.011"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of Virus-Like Particles for Vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"New Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/B978-0-12-418687-3.00027-6","article-title":"Transformation of E. coli Via electroporation","volume":"529","author":"Lessard","year":"2013","journal-title":"Methods Enzymol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nsmb785","article-title":"The Stoichiometry of Gag Protein in HIV-1","volume":"11","author":"Briggs","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 Years of Image Analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chroma.2016.05.053","article-title":"Purification of HIV-1 Gag Virus-Like Particles and Separation of Other Extracellular Particles","volume":"1455","author":"Steppert","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gonzalez-Dominguez, I., Puente-Massaguer, E., Cervera, L., and Godia, F. (2020). Quality Assessment of Virus-Like Particles at Single Particle Level: A Comparative Study. Viruses, 12.","DOI":"10.3390\/v12020223"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/1873-3468.12186","article-title":"Super-Resolved Insights into Human Immunodeficiency Virus Biology","volume":"590","author":"Hanne","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-Like Particles in Vaccine Development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Boix-Besora, A., Lorenzo, E., Lavado-Garcia, J., Godia, F., and Cervera, L. (2022). Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2. Vaccines, 10.","DOI":"10.3390\/vaccines10020250"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fontana, D., Garay, E., Cervera, L., Kratje, R., Prieto, C., and Godia, F. (2021). Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus. Vaccines, 9.","DOI":"10.3390\/vaccines9030251"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12033-016-9987-1","article-title":"Virus-Like Particles Derived from HIV-1 for Delivery of Nuclear Proteins: Improvement of Production and Activity by Protein Engineering","volume":"59","author":"Robert","year":"2017","journal-title":"Mol. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1093\/nar\/gkz605","article-title":"Delivering Cas9\/sgRNA Ribonucleoprotein (RNP) by Lentiviral Capsid-Based Bionanoparticles for Efficient \u2018Hit-and-Run\u2019 Genome Editing","volume":"47","author":"Lyu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109207","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted Delivery of CRISPR-Cas9 and Transgenes Enables Complex Immune Cell Engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1226359","article-title":"Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy","volume":"338","author":"Chojnacki","year":"2012","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/jssc.201600765","article-title":"Separation of HIV-1 Gag Virus-Like Particles from Vesicular Particles Impurities by Hydroxyl-Functionalized Monoliths","volume":"40","author":"Steppert","year":"2017","journal-title":"J. Sep. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1007\/s00253-018-9430-6","article-title":"Glycosylation Control Technologies for Recombinant Therapeutic Proteins","volume":"102","author":"Gupta","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-Positive Breast Cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","article-title":"HER2-Positive Gastric Cancer","volume":"17","author":"Boku","year":"2014","journal-title":"Gastric Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00253-017-8605-x","article-title":"Transient Gene Expression Optimization and Expression Vector Comparison to Improve HIV-1 VLP Production in HEK293 Cell Lines","volume":"102","author":"Fuenmayor","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/9\/11\/713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:52Z","timestamp":1760145712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/9\/11\/713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["bioengineering9110713"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering9110713","relation":{},"ISSN":["2306-5354"],"issn-type":[{"type":"electronic","value":"2306-5354"}],"subject":[],"published":{"date-parts":[[2022,11,19]]}}}